In this issue:
- 5-year outcomes with tisagenlecleucel in relapsed/ refractory LBCL
- Ibrutinib-rituximab vs. immunochemotherapy in previously untreated MCL
- Tafasitamab-lenalidomide rituximab in relapsed/ refractory FL
- Adding epcoritamab to lenalidomide-rituximab for relapsed/refractory FL
- CAR T-cell therapy and bispecific antibody sequence for LBCL
- Midostaurin + gemtuzumab ozogamicin as induction in FLT3-AML
- Targeting extramedullary myeloma with talquetamab + teclistamab
- Renal recovery/survival in MM with acute renal failure to cast nephropathy
- Impact of age on survival and mortality after autologous SCT in new MM
- Venetoclax-dexamethasone vs. pomalidomide-dexamethasone in t(11;14)-positive MM
Please login below to download this issue (PDF)